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Objective: Pain is the main problem for patients with osteoarthritis (OA). Pain is linked to inﬂammation,
but in OA a subset of patients suffers from pain without inﬂammation, indicating an alternative source of
pain. Nerve Growth Factor (NGF) inhibition is very efﬁcient in blocking pain during OA, but the source of
NGF is unclear. We hypothesize that damaged cartilage in OA releases Transforming Growth Factor-b
(TGF-b), which in turn stimulates chondrocytes to produce NGF.
Design: Murine and human chondrocyte cell lines, primary bovine and human chondrocytes, and
cartilage explants from bovine metacarpal joints and human OA joints were stimulated with TGF-b1 and/
or Interleukin-1 (IL-1)b. We analyzed NGF expression on mRNA level with QPCR and stained human OA
cartilage for NGF immunohistochemically. Cultures were additionally pre-incubated with inhibitors for
TAK1, Smad2/3 or Smad1/5/8 signaling to identify the TGF-b pathway inducing NGF.
Results: NGF expression was consistently induced in higher levels by TGF-b than IL-1 in all of our ex-
periments: murine, bovine and human origin, in cell lines, primary chondrocytes and explants cultures.
TAK1 inhibition consistently reduced TGF-b-induced NGF whereas it fully blocked IL-1b-induced NGF
expression. In contrast, ALK5-Smad2/3 inhibition fully blocked TGF-b-induced NGF expression. Despite
the large variation in basal NGF in human OA samples (mRNA and histology), TGF-b exposure led to a
consistent high level of NGF induction.
Conclusion: We show for the ﬁrst time that TGF-b induces NGF expression in chondrocytes, in a ALK5-
Smad2/3 dependent manner. This reveals a potential alternative non-inﬂammatory source of pain in OA.
© 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
The main symptom of osteoarthritis (OA) is joint pain. However,
what part of the joint is actually causing pain is somewhat obscure.
Pain is usually linked to inﬂammation1, but in early OA patients,
45% of patients report pain without any detectible inﬂammatory: E.N. Blaney Davidson, Rad-
atology, Huispost 272, Route
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ternational. Published by Elsevier Lcomponent like synovitis that could be driving their pain2. This
suggests a non-inﬂammatory cause for joint pain in at least a part of
OA patients.
In recent years, blocking Nerve Growth Factor (NGF) has sur-
faced as an efﬁcient way to inhibit pain, also in OA3e8.
NGF was elevated in an animal model of OA with cartilage
damage without joint inﬂammation, indicating a non-
inﬂammatory source of NGF in OA9,10. McNamee et al. investi-
gated NGF expression in a DMM model in whole knee joints and
found that tumour necrosis factor alpha (TNFa) induced NGF in the
post-operative phase, but TNFawas not responsible for later phases
of OA pain as anti-TNFa only abrogated pain in the post-operative
phase, not in late OA9. In contrast, NGF was key in both OA pha-
ses as soluble NGF receptor TrkAD5 prevented pain in both phases9.
Iannone et al. showed that chondrocytes produced NGF. NGF was
low in normal chondrocytes, increased in minor damaged cartilage,
and further enhanced in severely damaged human articulartd. All rights reserved.
Table I
Primers used for QPCR
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dependently increased NGF expression in OA articular chon-
drocytes up to 5.7 fold at 10 ng/ml, paralleled by NGF protein
release11. However, IL-1 still suggests an inﬂammatory component,
but does not explain a non-inﬂammatory source.
We were intrigued by the fact that chondrocytes produced NGF
and that levels were higher in damaged cartilage. In cartilage,
Transforming Growth Factor-b (TGF-b1) is stored in high
amounts12. Upon damage, TGF-b1 is released from the cartilage
extracellular matrix13. During OA, TGF-b is upregulated in carti-
lage14. In addition, high levels of TGF-b1 were found in serum of OA
patients with a strong correlation to a higher KellgreneLawrence
grade and WOMAC scale15. Clearly, TGF-b1 levels are linked to
cartilage damage and pain. By genome-wide gene expression
analysis in murine chondrocytes, we showed that only six genes
were enhanced by both IL-1b and TGF-b1: one of these genes was
NGF16. TGF-b1, like IL-1b can signal through TAK117,18. This led to
the hypothesis that TGF-b1 could be a driving factor in NGF
expression in articular chondrocytes in a TAK1-dependent manner.
We showed, for the ﬁrst time, that TGF-b1 induced NGF
expression in articular chondrocytes of murine, bovine and human
origin and that TGF-b1-induced NGF levels were higher than those
induced by IL-1b. We identiﬁed that TAK1 inhibition blocked NGF
expression by IL-1b, but only reduced TGF-b1-induced NGF
expression, thereby suggesting another major driving pathway for
NGF induction. Further investigation revealed that blocking ALK5-




The murine chondrocyte cell line H419 and human G6 chon-
drocyte cell line were used in monolayer20. The G6 cell line pro-
liferates at 32C and stops proliferating at 37C. H4 chondrocytes
were cultured in DMEM/F12 (Gibco, UK) with 50 mg/L gentamycin
(Centrafarm Services, the Netherlands) and 100 mg/L pyruvate
(Gibco, UK) with 5% FCS until use. G6 chondrocytes were cultured
in a 1:1 mixture of DMEM/F12 10% serum and Lonza Mesenchymal
Stem Cell Growth Medium (Lonza).
Bovine primary chondrocytes and cartilage explants
Primary bovine chondrocytes were isolated from cartilage of the
metacarpal joint, obtained from the local slaughterhouse within
3 h post-mortem. Cartilage was removed with a scalpel, obtaining
the non-calciﬁed cartilage layers. We used 3 mm punches to
generate equal size explants, which were randomly distributed
over the different conditions, four explants per condition per cow.
Cartilage explants were left untreated in DMEM/F12 0% FCS for
24 h prior to performing experiments. Alternatively for chondrocyte
isolation, cartilage was treated with 1.5 mg/ml Collagenase B
(Roche Diagnostics, Germany) in DMEM/F12 with 50 mg/L genta-
mycin and 100 mg/L pyrovate (1 g cartilage per 10 ml medium)
overnight. Chondrocyte suspensionwas ﬁltered (70 mm cell strainer
(Beckton Dickenson Biosciences), pelleted, washed in saline, and
seeded in a density of 1105 cells per cm2. Cells were cultured for 1
week to allow adherence prior to experiments.
Human OA primary chondrocytes or cartilage explants
Human OA cartilage was obtained from anonimized patients
undergoing joint-replacement surgery. Cartilage explants were
used, or chondrocytes were isolated as described for the bovinematerial, with the exception of the 1 week adherence prior to use,
as human chondrocytes were cultured in monolayer overnight
prior to stimulation.
Experiments
Cells or explants were serum starved overnight prior to stimu-
lation. Cultures were supplemented with recombinant human or
murine IL-1b (1 or 10 ng/ml) (R&D) for human or murine cells,
respectively, or recombinant human TGF-b1 (0.1, 1 or 10 ng/ml)
(Biolegend). In experiments with inhibitors, DMSO was used as
vehicle control. To block TAK1 activity, we used (5Z)-7-
oxozeaenol21 (oxozeanol in text, or oxo in ﬁgures) (Tocris Biosci-
ence) either 0.5 mM or 1 mM in the ﬁrst experiment, but thereafter
0.5 mM. To inhibit TGF-b signaling via ALK5-Smad2/3, 5 mM of the
ALK5 inhibitor SB-50512422 (SB in ﬁgures) (Sigma Aldrich) was
used. For inhibition of the Smad1/5/8 pathway 0.05 mM LDN23 was
used (Axon Medchem). Cultures were pre-incubated with in-
hibitors for 1 h prior to addition of IL-1b and/or TGF-b1. Twenty-
four hours after addition of IL-1b and/or TGF-b1, medium was
removed and TRI-reagent was added for RNA isolation. Unless
otherwise indicated a standard dose of 10 ng/ml of TGF-b1 and/or
10 ng/ml IL-1b was used for 24 h.
RNA isolation and Q-PCR
RNA isolation from explants was performed as previously
described in Ref. 24 using the RNeasy Fibrous tissue Mini Kit
(Qiagen) according to manufacturers protocol. RNA isolation from
chondrocytes was performed using TRI-reagent (SigmaeAldrich,
Germany) as previously described in Ref. 25. RNA concentration
was measured using a Nanodrop photospectrometer (Thermo Sci-
entiﬁc, USA), followed by cDNA preparation as previously described
in Ref. 25.
The cDNA was diluted 10 in ultra pure water, and gene
expression was measured using 1 mM of validated cDNA-speciﬁc
primers (Table I) (Biolegio, the Netherlands) in a quantitative real
time polymerase chain reaction (qPCR) using SYBRgreen master
mix (Applied Biosystems). The protocol was: after 10 min at 95C,
40 cycles of 15 s 95C and 1 min 60C each were run. A melting
curve was made to verify gene-speciﬁc ampliﬁcation. Data was
expressed as DDCt values corrected for GAPDH and controls, or
when multiple controls were used a eDct value was depicted. Be-
sides NGF, we used MMP3 (for bovine) or MMP13 (for mouse and
human) as a control for IL-1 responsiveness.
Immunohistochemistry
Cartilage explants were ﬁxed for 24 h in 4% paraformaldehyde.
Tissue was dehydrated with an automated tissue processing
apparatus (Miles Scientiﬁc Tissue-Tek VIP tissue processor; Miles
Scientiﬁc, now part of Bayer Corp., Emeryville, CA, USA) and
embedded in parafﬁn. Seven mm sections were stained
E.N. Blaney Davidson et al. / Osteoarthritis and Cartilage 23 (2015) 478e486480immunohistochemically as previously described in Ref. 26. Primary
antibody was anti-NGF (33,602 Santa Cruz). A biotinestreptavidin
detection system was used according to manufacturers protocol
(Vector Laboratories, Inc.). Bound complexes were visualized via
reaction with 30,30diaminobenzidine (Sigma Chemicals Co., Zwijn-
drecht, the Netherlands) and H2O2 resulting in a brown precipitate.
Sections were counterstained with heamatoxylin and mounted
with Permount.
Statistical analysis
There are experiments within this paper that were not suitable
for statistical analysis because we considered repetition of impor-
tant scientiﬁcally relevant groups in separate experiments and
different species of higher importance than repeating the same
experiments. For human OA chondrocytes we included many pa-
tients, but given the variation in basal NGF expression in human OA
patients we considered it would only be fair to the readers to
display their DCt values individually rather than pooling data and
calculating DDCt values. For the remainder of the experiments
statistical analysis was performed using Graphpad Prism software.
Gaussian distribution was tested using D'Agostino & Pearson
omnibus normality test followed by either a one-way ANOVA with
post-hoc Bonferroni comparison in case of a normal distribution, or
by a KruskalleWallis test followed by Dunn's comparison (see
ﬁgure legends).
Results
TGF-b1 induces NGF in chondrocytes in a ALK5-Smad2/3 and TAK-1
dependent manner
To investigate whether TGF-b1 induced NGF in chondrocytes,
we exposed the murine articular chondrocyte cell line H4 to 10 ng/
ml TGF-b1 for 24 h. This led to a 2.8 fold increase (1.5 Ct) in NGF
mRNA levels compared to non-treated controls [Fig. 1(A)]. This
increase was fully blocked by inhibiting TGF-b1 signaling via ALK5-
Smad2/3 with SB-505124 [Fig. 1(A)]. To investigate potential TAK1
dependency we exposed H4 chondrocytes to 10 ng/ml TGF-b1 with
or without oxozeaenol (0.5 or 1 mM). TGF-b1 again increased NGFFig. 1. TGF-b1 induces NGF in murine articular chondrocytes in an ALK5-Smad2/3 and TAK1
24 h in the presence or absence of ALK5-Smad2/3 signaling inhibitor SB-505124 and compa
TGF-b1 stimulation upregulated NGF expression compared to controls, which could be prev
KrusskalleWallis and Dunn's comparison (A). Murine H2 chondrocytes were stimulated with
prevent TAK1 signaling. TGF-b1 exposure resulted in an upregulation of NGF, which couldmRNA expression by 2.6 fold (1.4 Ct) [Fig. 1(B)]. When adding
appropriate DMSO dose to match the DMSO content of the oxo-
zeaenol 0.5 or 1 mM, TGF-b1 induced NGF expression increased by
3.2 and 4 fold (1.7 and 2.0 Ct), respectively. Preventing TGF-b1
signaling via TAK1 with oxozeaenol prevented TGF-b1 induced
NGF-expression in both 0.5 and 1.0 mM oxozeaenol [Fig. 1(B)]. Our
data clearly show for the ﬁrst time that TGF-b1 is capable of
elevating NGF mRNA expression in chondrocytes using ALK5-
Smad2/3 and TAK1 dependent.
TGF-b1 induces higher NGF expression than IL-1b in human
chondrocytes
To investigate whether TGF-b1 induced NGF in human cells, we
stimulated human G6 chondrocytes with 10 ng/ml of IL-1b and
compared that to a series of dosages of TGF-b1 (0.1, 1 and 10 ng/ml)
in [Fig. 2(A)]. As expected, 10 ng/ml of IL-1 led to an increase in NGF
mRNA levels of 2.3 fold (1.2 Ct). Surprisingly, TGF-b1 exposure
increased NGF mRNA even higher by 10.6 fold (3.4 Ct) and 6.1 fold
(2.6 Ct) in dosages of 1 and 10 ng/ml, respectively [Fig. 2(A)]. This
shows that 1 ng/ml of TGF-b1 induced NGF expression that was 4.6
fold (2.2 Ct) higher compared to a high dose of IL-1b (10 ng/ml)
[Fig. 2(A)]. Increasing the TGF-b1 dose from 1 to 10 ng/ml did not
result in higher NGF levels, which might suggest a maximum level
of NGF induction was already reached at 1 ng/ml of TGF-b1. These
data show that TGF-b1 is more potent in inducing NGF than IL-1b.
IL-1b and TGF-b1 are not additive in inducing NGF expression
To reveal whether or not TGF-b1and IL-1b could have an addi-
tive effect on NGF-expression in human G6 chondrocytes we
combined IL-1b and TGF-b1 in 1 and 10 ng/ml combinations. Again,
TGF-b11 and 10 ng/ml had equal effects in upregulating NGFmRNA
levels of 17.7 fold (4.1 Ct) and 24.3 fold (4.6 Ct), respectively. Again,
IL-1b exposure yielded lower NGF expression compared to TGF-b1
of 4.6 fold (2.2 Ct) and 6.1 fold (2.6 Ct) by 1 ng/ml and 10 ng/ml of IL-
1b, respectively. Combining TGF-b1 (either 1 ng/ml or 10 ng/ml)
with IL-1b (10 ng/ml) revealed no additive effect on NGF expression
in any combination, but rather NGF levels were similar to the cor-
responding TGF-b1 levels without IL-1b [Fig. 2(B)]. Given thedependent manner. Murine H4 chondrocytes were stimulated with 10 ng/ml TGF-b1 for
red to controls. RNA was isolated and QPCR was performed for NGF mRNA expression.
ented by inhibiting ALK5-Smad2/3 signaling. Statistical analysis was performed using
10 ng/ml of TGF-b1 for 24 h in the presence or absence of 0.5 mM or 1 mM oxozeaenol to
be prevented by blocking TAK1 (B).
Fig. 2. TGF-b1 induces NGF expression in human chondrocytes in higher levels than IL-1b; TGF-b1 and IL-1b do not have an additive effect on NGF expression. Human G6
chondrocytes were stimulated with TGF-b1 or IL-1b for 24 h, followed by RNA isolation and QPCR for NGF expression. Clearly, TGF-b1 induced higher levels of NGF compared to IL-
1b already at a dose of 1 ng/ml TGF-b1 (A). When TGF-b1 and IL-1b were combined, NGF levels were not enhanced showing a lack of additive effect of TGF-b1 and IL-1 b (B).
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additive effect, we wanted to conﬁrm IL-1b responsiveness and
therefore additionally measured MMP13 mRNA expression. TGF-b1
stimulation alone upregulated MMP13 by 3.26 Ct and 1.99 Ct in
1 ng/ml and 10 ng/ml, respectively, whereas IL-1b stimulation
resulted in an increase of 6.87 Ct and 6.77 Ct in 1 ng/ml and 10 ng/
ml, respectively. IL-1b 1 ng with TGF-b1 1 ng/ml or 10 ng/ml
resulted in a mean increase in MMP13 expression of 8.57 Ct and
7.81 Ct, respectively and using IL-1b 10 ng/ml with TGF-b1 1 ng/ml
or 10 ng/ml increased MMP13 expression with 8.63 Ct and 8.15 Ct.
Thus IL-1b increased MMP13 expression thereby conﬁrming IL-1b
responsiveness.
In primary bovine chondrocytes, TGF-b1 more potently induces NGF
expression than IL-1b
So far, we used chondrocyte cell lines. To conﬁrm our ﬁndings in
primary chondrocytes, we freshly isolated chondrocytes from
bovine metacarpal joints and stimulated those with TGF-b1 (1 and
10 ng/ml), IL-1b (1 or 10 ng/ml) or a combination of TGF-b11 ng/ml
with IL-1b 10 ng/ml [Fig. 3(A)]. This again showed that TGF-b1-
induced NGF mRNA expression was comparable between 1 and
10 ng/ml leading to a 16 fold (4.0 Ct) and 19.7 fold (4.3 Ct) increase,
respectively. This was again higher than NGF levels induced by IL-
1b, which were 2.6 fold (1.4 Ct) and 3.7 fold (1.9 Ct) for 1 and 10 ng/
ml, respectively. Combining TGF-b1 with IL-1b did not further
enhance NGF expression beyond TGF-b1 induced levels. Pre-
incubation with TAK1-inhibitor oxozeaenol reduced NGF expres-
sion in all groups [Fig. 3(A)]. However, TGF-b1stimulated groups
with oxozeanol all still had elevated levels of NGF compared to
baseline. Overall these data indicate that TGF-b1 stimulated NGF
expression is only partially TAK1-dependent, whereas IL-1b fully
relies on TAK1 signaling.
TGF-b1 increases NGF expression in bovine articular cartilage
explants
From experience we know that isolated chondrocytes can
respond differently from intact cartilage. To more closely mimic
in vivo articular cartilage, we freshly isolated cartilage explants
from healthy bovine metacarpal joints, and exposed these to TGF-b1 and IL-1b. Isolated explants were left untreated for 24 h to reach
a state of equilibrium. When comparing values of control samples
30 h after isolation to snap frozen samples, we found that NGF
levels were increased. The NGF levels had restored to baseline after
48 h (24 h equilibrium þ 24 h in experiment). Therefore, we used
the 24 h stimulation after 24 h equilibrium for the remainder of our
explants experiments. Upon TGF-b1 exposure, we again found a
signiﬁcant increase in NGF mRNA expression of 26 fold (4.7 Ct) on
average compared to controls, whereas IL-1b stimulation resulted
in an average increase of 2.1 fold (1.1 Ct), which was not signiﬁ-
cantly different from controls [Fig. 3(B)]. Combining TGF-b1 with
IL-1b again showed no additional effect on NGF expression levels.
These data conﬁrm that also in intact articular cartilage, TGF-b1
induces NGF mRNA expression levels that are higher than those
induced by IL-1b [Fig. 3(B)]. We again wanted to conﬁrm IL-1b
responsiveness in these samples and therefore measured MMP3
expression as MMP13 expression is below detection limit in bovine
cartilage explants. This showed a signiﬁcant increase in MMP3
expression in samples containing IL-1b, thereby conﬁrming IL-1b
responsiveness [Fig. 3(C)].
TGF-b1 induced NGF in bovine articular cartilage runs via ALK5-
Smad2/3
As oxozeaenol could partially reduce TGF-b1-induced NGF
expression we wanted to investigate if TGF-b1 signaling induces
NGF in cartilage in a similar way [Fig. 3(C)]. Therefore, we stimu-
lated cartilage explants of four different cows to TGF-b1 with or
without inhibitors for TGF-b1 signaling via ALK5-Smad2/3 (SB-
505124), TGF-b1 signaling via Smad1/5/8 (LDN) or TAK1 (oxo-
zeaenol).TGF-b1 induced a 58.9 fold increase (5.9 Ct) compared to
control. When comparing TGF-b1 þ DMSO to TGF-b1 with in-
hibitors, TAK1 inhibition reduced TGF-b1-induced NGF expression
by 3.4 fold (1.8 Ct), but this was not signiﬁcant. Blocking Smad1/5/8
signaling could not inhibit TGF-b1-induced NGF expression at all. In
contrast, only blocking ALK5-Smad2/3 signaling was capable of
signiﬁcantly reducing TGF-b1-induced NGF expression (reduction
of 55.6 fold (5.8 Ct). This shows that in intact articular cartilage,
TGF-b1 signaling via ALK5-Smad2/3 induces NGF and that there
might be a small role for TAK1 in TGF-b1 induced NGF expression,
whereas Smad1/5/8 signaling is not involved.
Fig. 3. TGF-b1 induces higher levels of NGF than IL-1b in bovine chondrocytes and bovine articular cartilage in a ALK5-Smad2/3 and partially TAK1 dependent manner. Primary
bovine chondrocytes isolated from the bovine metacarpophelangeal joint were stimulated with TGF-b1 or IL-1b or both with or without oxozeaenol. Both TGF-b1 and IL-1b induced
NGF, but TGF-b1 induced NGF levels were much higher. Co-incubation with oxozeaenol, thereby preventing TAK1 signaling could reduce TGF-b1-induced NGF expression, and fully
reverse IL-1b induced NGF expression (A). Bovine articular cartilage explants were stimulated with TGF-b1 or IL-1b or a combination of both for 24 h after which mRNAwas isolated
to measure NGF expression. This shows that TGF-b1 induced NGF expression is higher than IL-1b induced NGF expression (B). Bovine articular cartilage was stimulated with TGF-b1
with or without inhibitors for ALK5-Smad2/3 signaling (SB-505124) 5 mM, Smad 1/5/8 signaling (LDN) 0.05 mM or TAK1 signaling (oxozeaenol) 0.5 mM for 24 h after which RNA was
isolated to measure NGF expression. This showed that TGF-b1 induced NGF expression could only be fully blocked in the presence of SB-505124, could not be blocked by LDN and
slightly reduced by oxozeaenol (C). Statistical analysis was performed using KrusskalleWallis and Dunn's comparison.
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Until now we investigated the effect of TGF-b1 on healthy
articular chondrocytes and intact cartilage. However, people
experience pain during OA. We wanted to investigate whether
human OA chondrocytes were also capable of upregulating NGF in
response to TGF-b1 and IL-1b. We freshly isolated chondrocytes
from human OA cartilage and treated those with TGF-b1 or IL-1b.
Similar to prior results, IL-1b induced an increase in NGF mRNA
expression of 6.1 fold (2.6 Ct) on average whereas TGF-b1 induced
an increase of 18.4 fold (4.2 Ct) on average [Fig. 4(A)]. We included
MMP13 expression to conﬁrm IL-1b responsiveness in these
samples [Fig. 4(B)]. The most striking observation in these human
OA samples was not so much the induced levels, but rather the
massive variation in NGF mRNA expression in controls. We re-
ordered the patients in the graph to clarify the large spread in
basal NGF levels between OA patients, which clearly showed that
upon induction with IL-1b or TGF-b1the levels of NGF mRNA seem
to level out to a certain threshold, irrespective of the background
levels. We isolated intact cartilage for three random OA patients
and stained these for NGF with immunohistochemistry whichillustrated that the staining patterns of NGF protein expression
were very different for each patient [Fig. 4(C)]. Whereas the ﬁrst
sample showed a light positive, but diffuse staining throughout
the entire cell, sample 2 showed very intense nuclear staining, but
not all cells were positive. The third showed a combination of both
types of staining and some negative cells as well. Areas that had
less damage seemed to contain less NGF positive cells, but since
these were only three patients we cannot draw hard conclusions
on this. However, our data underlines the diversity in NGF
expression in human OA. Moreover, our stimulation data suggests
that irrespective of the basal levels of NGF, upon stimulation with
IL-1b or TGF-b1 the chondrocytes will produce a relative
maximum level of NGF mRNA compared to GAPDH, which again
generally seems to be higher for TGF-b1 stimulation than IL-1b
stimulation.
In human OA intact cartilage TGF-b1 induction of NGF is ALK5-
Smad2/3 dependent
We identiﬁed that TGF-b1-induced NGF was ALK5-Smad2/3
dependent in bovine and murine chondrocytes. We wanted to
Fig. 4. TGF-b1 induces higher NGF expression than IL-1bin human primary OA chondrocytes, but basal NGF levels show very high variation. Human primary OA chondrocytes were
isolated from patients undergoing total joint replacement surgery after informed consent. After isolation, chondrocytes were stimulated with TGF-b1 or IL-1b for 24 h followed by
RNA isolation and Q-PCR for NGF. Clearly, TGF-b1 stimulated samples reached higher levels of NGF than IL-1b stimulated samples. However, a striking observation was that the basal
levels of NGF in human OA chondrocytes showed a very large variation (A). In these samples MMP13 was measured to ensure IL-1bresponsiveness which showed that IL-1b indeed
induced MMP13 whereas TGF-b1 inhibited MMP13 Statistical analysis was performed using KrusskalleWallis and Dunn's comparison (B). Immunohistochemistry for NGF was
performed on articular cartilage of three random OA patients showing diversity in NGF protein expression (C). Human OA cartilage explants were stimulated with TGF-b1 with or
without an inhibitor for ALK5-Smad2/3 signaling (SB-505124) 5 mMfor 24 h after which RNA was isolated to measure NGF expression. Co-incubation with SB-505124 resulted in a
clear blockage of TGF-b1 induced NGF expression. After normality test, analysis was performed with a one-way ANOVA and Bonferroni for comparison (D).
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human OA cartilage explants to TGF-b1and combined this with
ALK5-Smad2/3 inhibition (SB-505124). We found that TGF-b1
induced a 6.5 fold increase of NGF (2.7 Ct) and that this was fully
blocked when ALK5-Smad2/3 signaling was prevented in all but
one patient [Fig. 4(D)]. This shows that even in OA cartilage, TGF-b1
can induce NGF via ALK5-Smad2/3.Discussion
NGF has been identiﬁed as a potential target for pain therapy in
OA. Iannone et al. showed that chondrocytes produce NGF and that
levels of NGF were linked to cartilage damage10. In articular carti-
lage, TGF-b1 is stored in high amounts and is released upon dam-
age12. Since there are patients with pain without any inﬂammatory
E.N. Blaney Davidson et al. / Osteoarthritis and Cartilage 23 (2015) 478e486484component27, we hypothesized that the source of NGF might be
TGF-b released from the cartilage. We showed that TGF-b1 induced
NGF in articular cartilage via ALK5-Smad2/3 and these levels of NGF
were much higher than those achieved by IL-1b. This indicates that
the non-inﬂammatory induction of NGF might have an even higher
impact than presumed until now.
As NGF was originally considered driven by inﬂammatory
mediators, IL-1b and TNFa have been in focus as inducing factors.
In synovial OA ﬁbroblasts, IL-1b and TNFa were capable of
inducing NGF27. However, the same authors identiﬁed that in
experimental arthritis, IL-1b, but not TNFa increased NGF and that
TNFa even lowered constitutive NGF amounts in murine knee
joints28. TNFa, however, enhanced IL-1b-induced NGF indicating
an indirect effect of TNFa and IL-1b on NGF. The tissue of origin
was unknown as whole knee joints were used. We compared IL-1b
to TGF-b1 as a reference for the extent of NGF induction. In all our
experiments IL-1b induced NGF, but TGF-b1 was far more potent,
even when using a low dose of 1 ng/ml TGF-b1 compared to IL-1b
10 ng/ml. This dose of IL-1b is the same as used by Pecchi et al.11.
They showed a basal value of NGF protein of approximately 15 pg/
ml. We show that inhibiting ALK5-Smad2/3 signaling with SB-
505124 reduced values to lower than controls (not signiﬁcant).
This could indicate that endogenous basal NGF levels rely on TGF-b
as well.
Pecchi et al. showed that mouse and human chondrocytes dose-
dependently increased NGF expression, onmRNA level and protein,
when exposed to IL-1b11. Mechanical stimulation also induced NGF,
but this could not be enhanced by IL-1b. In fact, their ﬁnding could
rely on TGF-b1 as a source of NGF induction, as we recently pub-
lished that Smad2/3 signaling was enhanced by mechanical stim-
ulation29. Moreover, we found that IL-1b could not enhance TGF-
b1-induced NGF expression, which could explain why IL-1b could
not enhance NGF when combined with mechanical stimulation in
Pecchi's experiments.
As both IL-1b and TGF-b1 can signal via TAK1, we initially
thought this could be the common pathway driving NGF. Moreover,
our prior ﬁnding of NGF being one out of only six genes that were
not counteracted, but rather enhanced by TGF-b1 and IL-1b,
strengthened our idea16. Indeed we found that TAK1 inhibition
decreased TGF-b1-induced NGF expression, but not to the extent
that we had originally expected. In contrast, IL-1b-induced NGF
expression was fully blocked by inhibition of TAK1, thereby con-
ﬁrming TAK1 dependency. This indicated involvement of another
pathway in TGF-b1-induced NGF expression. By blocking different
pathways activated by TGF-b1, we identiﬁed that TGF-b1-induced
NGF in chondrocytes and cartilage explants was fully ALK5-
Smad2/3 dependent.
In pancreatic cells it was shown that TGF-b1 induced NGF via
ALK530. This fully matches our data in chondrocytes, where we
show that TGF-b1 relies on ALK5-Smad2/3 signaling for induction
of NGF. In line with that, Braunger et al. showed in retinal pro-
genitor cells of TGF-b1 receptor II deﬁcient mice, Smad3 phos-
phorylation was decreased, which led to lower levels of NGF
mRNA. Similarly, mice deﬁcient in Smad7, which is a TGF-b1
signaling inhibitor, had higher Smad3 phosphorylation and higher
levels of NGF mRNA31. In rat hippocampus, TGF-b1 increased NGF
mRNA expression in vivo32. Interestingly, Yu et al. showed four
different transcripts of NGF that were differentially expressed
comparing mouse and rat spinal cord and brain cells. This
potentially relies on multiple TGF-b1 responsive elements in the
NGF promoters located upstream of exons 1 and 333. TGF-b1 could
induce NGF in astrocytes and glioma cells, but not in neuronal
cells, whereas all cells expressed the same TGF-b1 receptors. It was
concluded that differences were on a transcriptional level. They
showed that in different cell types different combinations of NGFtranscripts were induced by TGF-b1. We did not ﬁnd species dif-
ferences, but clearly IL-1b and TGF-b1 showed different levels of
NGF expression, which could correspond to different transcripts
being expressed.
In human OA cartilage, we found that basal levels of NGF were
highly different between patients, which was reﬂected by differ-
ences in immunohistochemical NGF staining. The ﬁnding of nuclear
NGF staining could point towards a nuclear translocation as pre-
viously found by Yanker et al.34. We observed that intact cartilage
areas showed less NGF staining compared to damaged areas, but
given the limited number of patients we are reluctant to conclude
on that. However, it does ﬁt the data of Iannone et al. who also
found that damaged cartilage expressed more NGF10. Strikingly,
despite the vast differences in basal NGF levels, stimulating these
highly variable samples with either TGF-b1 or IL-1b, resulted in
similar levels of NGF expression for which the height of expression
was dependent on the stimulus. TGF-b1-induced NGF was overall
higher than the IL-1b-induced NGF. This again points towards a
potential different regulatory mechanism: ALK5-Smad2/3 vs TAK1
for TGF-b1 and IL-1b, respectively.
In this study we included multiple species and monolayer vs
tissue explants culture to ensure NGF-induction was not limited by
method or species selected. However, this introduced a limitation
where for some experiments a low number of individual samples
were used in which case statistical analysis was not possible.
Therefore it is not possible to extrapolate beyond current experi-
ments when sample number was low.
In conclusion, we show that TGF-b1 is a very potent inducer of
NGF expression in chondrocytes and cartilage and its induction of
NGF can be higher than IL-1b. Moreover, we show that TGF-b1-
induced NGF expression relies on ALK5-Smad2/3 signaling, even
in human OA cartilage. In addition, we show that TGF-b1 induced
NGF expression can be reduced by TAK1 inhibition. In contrast, IL-
1b induced NGF expression is fully TAK1 dependent. Overall our
data strongly suggest that NGF induced by TGF-b1 in chondrocytes
could be a prominent alternative, non-inﬂammatory source of pain
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